EGFR and cancer: As mutation or overexpression of EGFR or Ras that deregulate EGFR/MAPK signaling are quite common in human cancers and NatB subunits are significant unfavorable prognostic markers for human cancers [57,58,59], our results could potentially provide a new strategy to develop therapeutic interventions for these cancers.